ID   HEL/TGR
AC   CVCL_4Z61
DR   cancercelllines; CVCL_4Z61
DR   Wikidata; Q54882508
RX   PubMed=21976548;
CC   Population: Caucasian.
CC   Selected for resistance to: ChEBI; CHEBI:90304; TG101209 (N-(tert-butyl)-3-((5-methyl-2-((4-(4-methylpiperazin-1-yl)phenyl)amino)pyrimidin-4-yl)amino)benzenesulfonamide).
CC   Sequence variation: Mutation; HGNC; 6192; JAK2; Simple; p.Val617Phe (c.1849G>T); ClinVar=VCV000014662; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Met133Lys (c.398T>A); ClinVar=VCV002430159; Zygosity=Homozygous (from parent cell line).
CC   Donor information: Originally the patient was suffering from Hodgkin lymphoma.
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
DI   NCIt; C7152; Erythroleukemia
DI   ORDO; Orphanet_318; Acute erythroid leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_2481 ! HEL 92.1.7
SX   Male
AG   30Y
CA   Cancer cell line
DT   Created: 14-12-15; Last updated: 05-10-23; Version: 11
//
RX   PubMed=21976548; DOI=10.1158/1078-0432.CCR-11-1541;
RA   Fiskus W., Verstovsek S., Manshouri T., Rao R., Balusu R.,
RA   Venkannagari S., Nalabothula N., Ha K., Smith J.E., Hembruff S.L.,
RA   Abhyankar S., McGuirk J.P., Bhalla K.N.;
RT   "Heat shock protein 90 inhibitor is synergistic with JAK2 inhibitor
RT   and overcomes resistance to JAK2-TKI in human myeloproliferative
RT   neoplasm cells.";
RL   Clin. Cancer Res. 17:7347-7358(2011).
//